Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 5/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104359 | 0.84 | HPGD (0.60) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL104400 | 0.83 | KMT2A (0.78) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14200335 | 0.81 | HSP90AA1 (0.58) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12985827 | 0.80 | POLB (0.57) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16860673 | 0.80 | GLRA1 (0.63) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL12591836 | 0.79 | KMT2A (0.71) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL24976158 | 0.79 | HPGD (0.74) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17465250 | 0.78 | KMT2A (0.85) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12545825 | 0.77 | HPGD (0.65) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12545840 | 0.77 | HPGD (0.70) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | KMT2A 2424/4885MEN1 4301/4885ALDH1A1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.